Takeda Pharmaceutical (TKPHF) Depreciation & Amortization (CF) (2018 - 2026)

Takeda Pharmaceutical's Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 15.99% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.8 billion (down 4.09% YoY), while the FY2026 annual figure was $4.8 billion, down 4.16% from the prior year.
• Depreciation & Amortization (CF) was $1.0 billion for Q1 2026 at Takeda Pharmaceutical, down from $1.2 billion in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.3 billion in Q1 2022 to a low of $1.0 billion in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $1.2 billion across 5 years, with a median of $1.3 billion in 2023.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) increased 4.11% in 2023, then declined 15.99% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.3 billion in 2022, then grew by 1.08% to $1.3 billion in 2023, then fell by 2.83% to $1.2 billion in 2024, then rose by 0.73% to $1.2 billion in 2025, then retreated by 15.65% to $1.0 billion in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.